Acute Coronary Syndrome in Patients With COVID-19

Completed

• Conditions: Myocardial Infarction; COVID-19; Myocardium; Injury; Acute Coronary Syndrome
• Interventions: Procedure: Coronary angiography

• Registration Number: NCT05732597
• Lead Sponsor: Bulgarian Cardiac Institute

Brief Summary

The aim of this study was to find a clinical or laboratory parameter, that would help in distinguishing between COVID-19 patients with myocardial infarction (MI), who have an infarct-related artery (IRA) and therefore, require immediate revascularization, and those, who have no IRA.

Detailed Description

The coronavirus pandemic has hit the world with its vast contagiousness, high morbidity, and mortality Apart from the direct damage to the lung tissue, the corona virus infection is associated with multiple organ damage, including the heart. Emerging evidence reveals a direct correlation between COVID-19 and cardiovascular complications, such as heart failure, myocarditis, arrhythmias, conduction abnormalities and acute coronary syndromes. The SARS-CoV-2 infection can frequently induce coagulation abnormalities that are associated with cardiopulmonary deterioration and death as a possible complication in all patients, despite presence or absence of concomitant risk factors and diseases. In addition, many patients with severe COVID-19 undergo thromboembolic events, which seem to be related to this particular coagulopathy. One of the most unpleasant and life-threatening types of thromboembolism is the one involving the coronary circulation, thus causing a heart attack. Many additional problems arise due to this condition e.g., access to a Cath lab, exposure of additional medical personnel, more complications and increased mortality for the patients.

Invasive angiography for COVID-19 patients is logistically challenging and, in some cases, there is no intervention target, since microcirculatory disease and thrombosis is common in this group. Therefore, the investigators studied in detail the case series of 10 patients referred for primary percutaneous coronary intervention (pPCI) for MI in our catheterization laboratory during the course of COVID-19 infection. And the investigators set themselves the purpose to evaluate if there are some factors or parameters that could predict the presence of an interventional target - infarct related artery (IRA), prior to catheterization, and to determine their sensitivity and specificity.

Study Timeline

• Study Start: 2020-11-01
• Primary Completion: 2022-02-27
• Study Completion: 2022-02-27
• Study First Submitted: 2023-02-16
• Study First Submitted QC: 2023-02-16
• Study First Posted: 2023-02-17
• Status Verified: 2024-08
• Last Update Submitted: 2024-08-05
• Last Update Posted: 2024-08-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 26

Inclusion Criteria

• Acute coronary syndrome (ACS)
• COVID-19 infection

Exclusion Criteria

• No combination of ACS and COVID-19 infection

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients with ACS and no IRA	Coronary angiography	Patients with acute coronary syndrome (ACS) during a COVID-19 infection, who after undergoing coronary angiography - no infarct-related artery (IRA) is found
Patients with ACS and IRA	Coronary angiography	Patients with acute coronary syndrome (ACS) during a COVID-19 infection, who after undergoing coronary angiography - an infarct-related artery (IRA) is found

Primary Outcome Measures

Name	Time	Method
to find a clinical or laboratory parameter, that would help in distinguishing between COVID-19 patients with MI and IRA and those, who have no IRA	During the whole study

Trial Locations

Locations (1)

Heart and brain center of clinical excellence, University hospita, Pleven, Bulgaria; 🇧🇬 Pleven, Bulgaria